{"In": [0], "an": [1], "early-phase": [2], "study": [3], "involving": [4], "patients": [5, 27, 50], "with": [6, 17, 22, 28, 51], "advanced": [7], "non\u2013small-cell": [8], "lung": [9], "cancer": [10], "(NSCLC),": [11], "the": [12, 42], "response": [13], "rate": [14], "was": [15], "better": [16], "nivolumab": [18, 23, 46], "plus": [19, 47], "ipilimumab": [20, 48], "than": [21], "monotherapy,": [24], "particularly": [25], "among": [26], "tumors": [29], "that": [30], "expressed": [31], "programmed": [32], "death": [33], "ligand": [34], "1": [35], "(PD-L1).": [36], "Data": [37], "are": [38], "needed": [39], "to": [40], "assess": [41], "long-term": [43], "benefit": [44], "of": [45], "in": [49], "NSCLC.": [52]}